Results 31 to 40 of about 309,141 (294)

Durable response using regorafenib in an elderly patient with metastatic colorectal cancer: case report. [PDF]

, 2015
Regorafenib, an oral multikinase inhibitor, was approved in September 2012 by the US Food and Drug Administration for the treatment of patients with metastatic colorectal cancer.
Herman, June, Kain, Tatiana, Seery, Tara, Tang, Ronald   +3 more
core   +3 more sources

Immunodivergence in Metastatic Colorectal Cancer [PDF]

Cancer Cell, 2018
Van den Eynde et al. publish in this issue of Cancer Cell that metastatic colorectal cancer shows marked heterogeneity in T cell infiltration among different lesions and patients. Measurements of T cell infiltration in metastases by immunoscore offer some prognostic information and support immune editing by coevolving adaptive immune responses.
Carlos E, de Andrea, Kurt A, Schalper, Miguel F, Sanmamed, Ignacio, Melero   +3 more
openaire   +2 more sources

Aflibercept in the Treatment of Metastatic Colorectal Cancer

Clinical Medicine Insights: Oncology, 2012
Colorectal cancer is the third most common cancer in the US. In recent decades, an improved understanding of the role of the angiogenesis pathway in colorectal cancer has led to advancements in treatment.
Tzu-Fei Wang, Albert Craig Lockhart
doaj   +1 more source

TGF-β and SMAD2/4 Expression in Nonmetastatic and Metastatic Colorectal Cancer Patients [PDF]

BIO Web of Conferences
Colorectal cancer (CRC) is the third most common and second cancer with the highest mortality rate in the world. The leading cause of death in colorectal cancer patients is cancer that has metastasized, with the most common site of metastasis being the ...
Mardiah Ainul, Susanto Hendra, Lestari Sri Rahayu   +2 more
doaj   +1 more source

Weekly irinotecan in a patient with metastatic colorectal cancer on hemodialysis due to chronic renal failure [PDF]

, 2002
Background: The cytotoxic treatment of patients suffering from advanced or metastatic cancer undergoing hemodialysis due to chronic renal failure still remains a problem, since for those patients pharmacokinetic and pharmacodynamic data on most cytotoxic
Hacker, U., Heinemann, Volker, Schalhorn, A., Stemmler, J., Weise, A.   +4 more
core   +1 more source

Identification of O-Linked Glycoproteins Binding to the Lectin Helix pomatia Agglutinin as Markers of Metastatic Colorectal Cancer. [PDF]

PLoS ONE, 2015
Protein glycosylation is an important post-translational modification shown to be altered in all tumour types studied to date. Mucin glycoproteins have been established as important carriers of O-linked glycans but other glycoproteins exhibiting altered ...
Diluka Peiris, Marlène Ossondo, Simon Fry, Marilena Loizidou, Juliette Smith-Ravin, Miriam V Dwek   +5 more
doaj   +1 more source

Integrative analysis of the colorectal cancer proteome : potential clinical impact [PDF]

, 2016
Peer ...
Alnabulsi, Abdo, Murray, Graeme I.
core   +2 more sources

FOLFIRINOX-R study design: a phase I/II trial of FOLFIRINOX plus regorafenib as first line therapy in patients with unresectable RAS-mutated metastatic colorectal cancer

BMC Cancer, 2021
Background The chemotherapy triplet FOLFOXIRI combined to the anti-VEGF antibody bevacizumab is an option in selected patients with metastatic colorectal cancer.
Antoine Adenis, Thibault Mazard, Julien Fraisse, Patrick Chalbos, Brice Pastor, Ludovic Evesque, Francois Ghiringhelli, Caroline Mollevi, Stéphanie Delaine, Marc Ychou   +9 more
doaj   +1 more source

Cytoplasmic p21 promotes stemness of colon cancer cells via activation of the NFκB pathway

Molecular Oncology, EarlyView.
Cytoplasmic p21 promotes colorectal cancer stem cell (CSC) features by destabilizing the NFκB–IκB complex, activating NFκB signaling, and upregulating BCL‐xL and COX2. In contrast to nuclear p21, cytoplasmic p21 enhances spheroid formation and stemness transcription factor CD133.
Arnatchai Maiuthed, Kerstin Huebner, Katharina Erlenbach‐Wuensch, Chuanpit Hampel, Daniela Thalheim, Adriana Vial‐Roehe, Bodee Nutho, Susanne Merkel, Arndt Hartmann, Pithi Chanvorachote, Regine Schneider‐Stock   +10 more
wiley   +1 more source

Molecular and genetic targets within metastatic colorectal cancer and associated novel treatment advancements

Frontiers in Oncology, 2023
Colorectal cancer results in the deaths of hundreds of thousands of patients worldwide each year, with incidence expected to rise over the next two decades.
Christopher G. Cann, Michael B. LaPelusa, Sarah K. Cimino, Cathy Eng   +3 more
doaj   +1 more source